AC
PRTK

Aisling Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Aisling Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-482,680
Closed -$11.6M – 16
2017
Q2 		$11.6M Hold
482,680
– – 1.99% 7
2017
Q1 		$9.29M Hold
482,680
– – 1.69% 10
2016
Q4 		$7.43M Hold
482,680
– – 1.73% 12
2016
Q3 		$6.28M Hold
482,680
– – 1.29% 15
2016
Q2 		$6.71M Sell
482,680
-200,000
-29% -$2.94M 1.59% 16
2016
Q1 		$10.4M Hold
682,680
– – 2.07% 16
2015
Q4 		$12.9M Hold
682,680
– – 2.23% 15
2015
Q3 		$13M Hold
682,680
– – 2.28% 15
2015
Q2 		$17.6M Hold
682,680
– – 2.62% 14
2015
Q1 		$21.3M Hold
682,680
– – 2.79% 13
2014
Q4 		$26.3M Buy
+682,680
New +$16.3M 3.99% 10

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Aisling Capital's PRTK Position: Q3 2017 in Review

Aisling Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 482,680 shares — an estimated $11.6M sold.

Aisling Capital first reported a position in PRTK in Q4 2014 and held it in 11 quarters. The position peaked at $26.3M in Q4 2014. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

  • Aisling Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Aisling Capital sold 482,680 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $11.6M.
  • Aisling Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 11 quarters.
  • Aisling Capital's Paratek Pharmaceuticals, Inc. position peaked at $26.3M in Q4 2014.
  • 133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Aisling Capital's 13F filing for Q3 2017, filed 9 Nov 2017.